HT
Hisamitsu Pharmaceutical Co., Inc.
HTSUF · OTC
$29.00 +0.00% (+$0.00)
Market Cap ¥325.1B
P/E Ratio 18.50x
Div. Yield 2.84%
ROE 8.55%
Bulios Fair Price
$17.79
38.7% downside
Current Price
$29
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HTSUF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
63 /100
Fair P/E 18.50x
EV/EBITDA 15.11x
P/S 2.53x
Growth
73 /100
Growing EPS growth 17.06%
Rev. growth 7.36%
FCF growth 39.42%
Profitability
53 /100
Moderate Gross margin 57.05%
Net margin 14.01%
Op. margin 11.21%
Quality
31 /100
Poor ROIC 4.04%
ROE 8.55%
ROA 4.88%
Debt
100 /100
Low Debt/Equity 0.01x
Current ratio 4.08x
Int. coverage 2,381.26x
Stability
81 /100
Stable Beta 0.29x
Rev. volatility 2.78%
EPS volatility 10.71%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HTSUF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Kazuhide Nakatomi
Employees
2,759
Headquarters
Tosu